BTK and Ecchymosis: While ibrutinib has not been reported to induce similar lesions, ibrutinib itself is associated with an increased risk of bleeding, as common cutaneous toxicities related to Bruton tyrosine kinase inhibitors may commonly include ecchymosis and petechiae development.7